US OptionsDetailed Quotes
DVAX241220P12000
- 0.10
- 0.000.00%
15min DelayTrading Nov 27 14:32 ET
0.00High0.00Low
0.00Open0.10Pre Close0 Volume3 Open Interest12.00Strike Price0.00Turnover36.85%IV7.18%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.1795Delta0.2646Gamma128.20Leverage Ratio-0.0079Theta-0.0010Rho-23.02Eff Leverage0.0070Vega
Dynavax Technologies Stock Discussion
Dynavax Technologies Down Over 7%, On Track for Largest Percent Decrease Since August 2022 -- Data Talk
Dow Jones· 2 mins ago2mins
Dynavax Technologies Corporation ( DVAX ) is currently at $12.42, down $0.97 or 7.21%
--Would be lowest close since Nov. 7, 2024, when it closed at $12.02
--On pace for largest percent decrease since Aug. 17, 2022, when it fell 10.39%
--Currently down three of the past four days
--Currently down two consecutive days; down 8.1% ov...
Dynavax Announces $200 Million Share Repurchase Program
Dynavax (DVAX) reported strong Q3 2024 financial results, with HEPLISAV-Bachieving record quarterly net product revenue of $79.3 million, up 27% year-over-year. The company's total revenues reached $80.6 million, a 16% increase from Q3 2023. HEPLISAV-B's U.S. market share grew to 44%, with particularly strong performance in retail pharmacy (55%) and IDN segments (56%). The company expects the hepatitis B...
🗓️ Last week’s PDUFAs:
$Amgen (AMGN.US)$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb (BMY.US)$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies (DVAX.US)$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S (ASND.US)$ : Review extended to 8/14/24 🤔
⇒ YORV...
Dynavax: Crl States Application Did Not Provide Sufficient Data to Support Full Evaluation of Effectiveness or Safety of 4-Dose Regimen of Heplisav-B
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies (DVAX.US)$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S (ASND.US)$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals (XFOR.US)$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
$Pfizer (PFE.US)$ $Dynavax Technologies (DVAX.US)$ $Sandstorm Gold (SAND.US)$ $Bristol-Myers Squibb (BMY.US)$ $SPDR S&P Biotech ETF (XBI.US)$
Dr. Stock is bullish on SoFi, considering it a fundamental long-term play with potential growth. He's eagerly awaiting Q2 earnings to see if they stay on track to achieve profitability by Q4 2023. Dr. Stock talks about possible price drops in the short term, which could create great buying opportunities for the long term. He also discusses potential resistance levels and trade plays as the stock approaches key price points.
🚗 Stock #2 - Tes...
To analyze these stocks, Dr. Stock uses Moomoo, a platform where you can get up...
No comment yet